Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Rockwell Medical (RMTI) over the last 16 years, with Dec 2024 value amounting to $32.3 million.

  • Rockwell Medical's Shares Outstanding (Weighted Average) rose 10.96% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 10.96%. This contributed to the annual value of $32.3 million for FY2024, which is 13.44% up from last year.
  • As of FY2024, Rockwell Medical's Shares Outstanding (Weighted Average) stood at $32.3 million, which was up 13.44% from $28.5 million recorded in FY2023.
  • Rockwell Medical's 5-year Shares Outstanding (Weighted Average) high stood at $32.3 million for FY2024, and its period low was $8.5 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $24.1 million, with a median of $28.5 million in 2023.
  • Per our database at Business Quant, Rockwell Medical's Shares Outstanding (Weighted Average) decreased by 0.42% in 2021 and then surged by 144.91% in 2023.
  • Over the past 5 years, Rockwell Medical's Shares Outstanding (Weighted Average) (MRY) stood at $8.5 million in 2020, then rose by 0.42% to $8.5 million in 2021, then skyrocketed by 36.18% to $11.6 million in 2022, then soared by 144.91% to $28.5 million in 2023, then grew by 13.44% to $32.3 million in 2024.
  • Its last three reported values are $32.3 million in FY2024, $28.5 million for FY2023, and $11.6 million during FY2022.